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LIST OF ABBREVIATIONS 
ART - Antiretroviral Therapy  
AS ERAP2 - Alternatively Spliced Endoplasmic Reticulum Associated Aminopepetidase 
type2 
ERAP2 - Endoplasmic Reticulum Associated Aminopepetidase type2 
FL ERAP2 - Full-Length Endoplasmic Reticulum Associated Aminopepetidase type2  
Hap A - GG homozygous ERAP2 
Hap B - TT homozygous ERAP2 
HESN - HIV-Exposed Sero-Negatives 
HIV-1 - Human Immunodeficiency Virus 1 
MX2 – Myxovirus Resistance 2 
PBMCs - Peripheral Blood Mononuclear Cells  
SNP - Single Nucleotide Polymorphism  
TLR3 - Toll-like Receptor 3  
VL - Viral Load 
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 INTRODUCTION  
HIV-1 infection is not a genetic disease; nevertheless, genetic factors could influence its 
susceptibility and progression. First evidence of this assumption dates back to 1996, when 
a homozygous variant for CCR5 chemokine receptor, Δ32, has been described showing 
a strong association with HIV-1 sexually transmission (1). Indeed, different phenotypes 
associated with non-classical outcomes to HIV-1 exposure and infection have been 
observed, leading to the development of the "immunological advantage" concept; a 
condition where the genetic background allows to control HIV-1 infection/replication in 
fortunate patients (2, 3). Some of the genes so far associated  to this peculiar state include 
the ones briefly described hereafter. Endoplasmic Reticulum Associated Aminopeptidase 
type 2 (ERAP2) plays a key role in antigen presentation mechanisms. Trimming the N-
terminal region of peptides ERAP2 adjusts the final peptide length for optimal binding to 
HLA class I molecules and modulates specific CTL responses (4). Haplotype-specific 
alternative splicing of  ERAP2 gene results in either full-length (FL, hapA) or 
alternatively spliced (AS, haplotype B) mRNA; HapA is observed to be higher in HIV-
Exposed Sero-Negative (HESN) individuals suggesting its involvement in conferring 
natural resistance to HIV-infection (5, 6). APOBEC3H, part of the APOBEC3 family, 
controls HIV-1 resistance at different levels (7). HAPI APOBEC3H haplotype is 
associated with sexually protection in HIV-1 transmission (7). Myxovirus resistance 2 
(MX2) interferes with the viral replication decreasing nuclear viral DNA accumulation 
and integration (8). The G allele of rs2074560 in MX2 gene reveals protection from HIV-
1 infection regardless of the transmission route (9). Regarding Toll-like receptor 3 
(TLR3), in two HESN cohorts, a higher frequency of rs3775291 SNP (Leu412Phe) was 
observed suggesting protection against HIV-1 infection (10). Taking in mind that none of 
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the above-mentioned polymorphisms provides an absolute protection over HIV-1 
infection, we decided to verify if these genetic variants - individually or in combination- 
might modulate the initial immunological and virological responses to antiretroviral 
therapy (ART). 
 
MATERIALS AND METHODS 
Sample collection 
300 HIV-infected patients from the ICONA Foundation Study cohort undergoing a first 
ART regimen were enrolled in the study. These were a random sample of the cohort for 
which there were at least one year of virological follow-up and a full blood sample was 
collected at some point in the study. Blood samples were collected from each patient in 
EDTA Vacutainer® tubes. Immediately after collection, peripheral blood mononuclear 
cells (PBMCs) were isolated and stored at -80°C. Subsequently, cells were transferred to 
the laboratories of the University of Milan for genotyping analyses. Periodically (6 
months and 1 year) HIV-infected patients’ clinical parameters (genotype, gender, CD4+ 
cell count, viral load, therapies, year of infection, clinical evolution) were analyzed and 
inserted into a predisposed electronic database. The study was designed and conducted in 
accordance with the Declaration of Helsinki and approved by the Ethics Committee of 
the hospitals involved in the study. After thoroughly explaining the project and clarifying 
any doubt concerning the research, all subjects signed an informed consent and the 
biological material collected was anonymized to ensure the privacy of each individual. 
Genotyping 
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DNA was extracted by the Maxwell® RSC Instrument automated following a nucleic 
acid purification method (Promega, Madison, Wisconsin, USA) associated with 
Maxwell® RSC Blood DNA Kit Technical Manual (Promega, Madison, Wisconsin, 
USA). Genomic DNA was used as template for PCR amplification using TaqMan probes 
specifically designed to perform a SNP genotyping assay (Applied Biosystems, Foster 
City, CA, USA). The amplification and fluorescence reading were carried out as 
previously described. The list of the gene variants analyzed by this strategy and the code 
of the TaqMan assay used are listed in Supplementary Table I. 
Statistical analyses 
The allelic discrimination method was used to determine the frequency of each single 
nucleotide polymorphism (SNP). The main characteristics of the study population at the 
time of ART initiation were described and tabulated (Table I). Separate models were 
employed to evaluate the association between the detection of the genetic variants and 
HIV-RNA, CD4+ cell count and CD8+ cell count (as well as their ratio) responses to 
ART. For the HIV-RNA response, the time to achieving a value ≤50 copies/mL after ART 
initiation was evaluated by means of standard survival analysis and Kaplan-Meier curves. 
The date of the first HIV-RNA value ≤50 copies/mL after ART initiation (a single value) 
was used to define the time of achievement of viral suppression. Participants’ follow-up 
was censored at the date of their last available viral load. For each gene and all four 
endpoints (HIV-RNA, CD4+ cell count, CD8+ cell count and CD4/CD8 ratio) a linear 
mixed model was used to compare intercept and slopes according to variants detection. 
Variability between patients was controlled using random intercepts and slopes. Viral 
load (VL) was fitted in the log10 scale to achieve distribution symmetry. Besides testing 
the associations with each gene variant, also a genotypic score was constructed by 
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allocating 1-point every time a variant was detected and summing all points per 
participants (i.e. a patient in which ERAP2 rs2549782 G/G was detected as well as 
rs3775291 C/T or T/T for TL3 and none of the others would have a value of 2 for the 
score, etc.). In detail, participants were stratified in 3 groups for the survival analysis 
(with score values >3; 2-3 and 0-1) and comparing those with extremes scores in the 
mixed linear regression from fitting a binary variable. The score is referred as 
‘supergenotype’ throughout the results of this chapter. All models were fitted on the 
whole dataset of 300 participants and after restricting to 255 participants of Caucasian 
origins. 
 
RESULTS 
Analysis of allelic variants in the ICONA cohort 
Analysis of SNPs prevalence in the selected genes did not show any difference compared 
with the European population distribution reported in U.S. National Library of Medicine 
Database (Table IIA-B). The presence of single and combined polymorphisms is reported 
in Table IIC.  
 
Correlation between single allelic variants and clinical parameters at baseline and 1 
year after first ART administration  
We did not observe any significant association between the analyzed allelic variants and 
clinical parameters of HIV+ patients enrolled in the ICONA cohort at baseline 
(Supplementary Tables II-IV). No correlation between APOBEC3H, TLR3 and MX2 
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SNPs and either HIV-1 viral load or CD4+ or CD8+ T cell count slopes was observed in 
our cohort 12 months post cART administration (data not shown). Conversely, we 
observed an association between the rs2549782 GG variant of ERAP2 and the HIV viral 
load decay after first cART start (Figure 1A). After adjusting for age, gender, CD4+ T 
cell count and HIV-RNA at cART start, use of INSTI or >3 drugs, ART-naive and year 
of cART starting, a non-significant steeper decline in HIV VL was detected for GG 
genotype compared to GT and TT variants: difference in adjusted HIV-RNA mean 
change/year (GT/TT – GG): +0.36 log10 copies/mL; p=0.09. (26). 
Caucasian patients carrying this genotype showed a trend towards a steeper increase in 
CD4+ T cell count as well (difference in adjusted CD4+ mean change/year (GT/TT - 
GG)= -49 cells/mmc; p=0.19) (Figure 1 B).  As for CD8+ data in GG patients, TT/GT 
genotyped patients showed a significant decrease in CD8+ T cell count over the year 
(adjusted CD8+ mean change/year=-133 cells/mmc (95%CI: -205,-62.4), while the same 
marker in GG patients remained constant (as supported by the analysis showing a the 
significant difference in slope) (p=0.14) (Figure 1 C). Indeed, we observed no differences 
in CD8+ T cell count over 1 year-treatment (adjusted CD8+ mean change/year=-12.2 
cells/mmc) (95%CI: -160,135.6). Nevertheless, independently from the genotype no 
significant differences in CD4+/CD8+ cell ratio were observed over time in our cohort 
(p=0.34) (Figure 1 D). 
 
Correlation between combined allelic variants and clinical parameters 
 One of the aims of this study was also to identify polymorphism combinations (a 
“supergenotype”) in genes that are considered to be protective in viral 
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infection/replication control and response to ART by monitoring the clinical parameters 
of interest (VL and CD4 or CD8 cell count). Therefore, a score (SNP score) was assigned 
to each SNP (Figure 2 A-C) in order to identify a combination of variants that could 
provide an immunological benefit in terms of infection progression and response to 
therapy. The analysis, however, did not show significant correlations between variant 
combinations and response to therapy either in terms of VL (Figure 2 D-E) or of CD4+ 
or CD8+ T cell count (Figure 2 F-G).  
 
 
DISCUSSION 
As per definition, the immune system of HIV-infected individuals is not characterized by 
the "immunological advantage" observed in HESN (2). However, one or more protective 
genetic variants could confer a better control over disease progression if compared with 
patients who do not express such haplotypes. Aim of this study was to investigate a 
possible correlation between response to ART and selected host genetic variants in HIV-
infected patients, with the goal to optimize pharmacological intervention in HIV-1-
infected subjects. Results showed that, allelic variants in ERAP2 gene result into a more 
favorable virologic and immunologic response to therapy. Indeed, a significant reduction 
in viral load and a trend in CD4+ cells recovery was observed at 12 months post ART 
initiation in GG homozygous (Hap A), compared to TT homozygous (Hap B) or G/T 
heterozygous patients at ERAP2 SNP rs2549782. Considering the key role played by  
ERAP2 in the activation of antiviral (11) and HIV-specific immune response (5, 6, 12), 
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it is possible to speculate that HapA ERAP2 generates more immunogenic peptides able 
to trigger a more efficient CTL HIV-specific response, even in ART-treated HIV patients  
As corollary of our results, a "super genotype" associated with a better response to ART 
response and characterized by the presence of several “protective” allele variants was not 
yet observed. Nevertheless, the preliminary results obtained upon analyzing ERAP2, 
warrant the usefulness of investigating the role of Hap A in a case/control study, both in 
the progression of the infection and in response to treatment. 
 
FIGURE LEGENDS 
Figure 1. Mean intercept and slope of log10 Viral Load (A), CD4+ T Cells (B), CD8+ T 
Cells (C) and ratio of CD4/CD8 + T cells (D) from fitting a mixed-linear model in 
Caucasian subjects of ICONA cohort according to ERAP2 genotype (data adjusted for 
age, gender, ratio and VL at cART, use of INSTI or >3 drugs, ART-naïve and year of 
cART starting  
Figure 2. SNP score assigned to each variant (A) and frequency-percent of total cohort 
subjects (B) and Caucasian subjects (C) related to the score. Mean intercept and slope of 
log10 Viral Load (D), CD4+ T Cells (F) and CD8+ T cells (G) after cART start from 
fitting a mixed-linear model in Caucasian subjects according to SNPs score strata (data 
adjusted for age, gender, ratio and VL at cART, use of INSTI or >3 drugs, ART-naive 
and year of starting ART) and Kaplan-Meier curves estimating the cumulative probability 
of virological success (E) according to SNPs score strata. 
 
  
11 
 
ACKNOWLEDGMENTS 
AUTHORS’ CONTRIBUTIONS 
M Clerici and M Biasin, conceived the study; EM Lor. wrote the paper; V Mercurio and 
SV Ibba performed the experiments; A Cozzi-Lepri analysed the data; S Lo Caputo 
revised the paper; A d'Arminio Monforte coordinate the Icona Foundation; A Tavelli 
contribuited to the data collection; C Venditti was involved in the bio-bank storage; F 
Castelli, A Castagna, A Gori, G Marchetti, and selected and enrolled the subjects included 
in the study. 
Conflict of interest statement 
All authors report no competing interest. 
  
12 
 
REFERENCES 
1. Deng H, Liu R, Ellmeier W, et al. Identification of a major co-receptor for primary 
isolates of HIV-1. Nature 1996; 381(6584), 661. 
2. Miyazawa M, Lopalco L, Mazzotta F, et al. The ‘immunologic advantage’of HIV-
exposed seronegative individuals. AIDS 2009; 23(2):161-175. 
3. Fenizia C, Rossignol J F, Clerici M, Biasin M. Genetic and immune determinants of 
immune activation in HIV-exposed seronegative individuals and their role in protection 
against HIV infection. Infection, Genetics and Evolution 2018; 66:325-334 
4. Stratikos E, Stern LJ Antigenic peptide trimming by ER aminopeptidases—Insights from 
structural studies. Molecular immunology 2013; 55(3-4):212-219. 
5. Cagliani R, Riva S, Biasin M, et al. Genetic diversity at endoplasmic reticulum 
aminopeptidases is maintained by balancing selection and is associated with natural 
resistance to HIV-1 infection. Human molecular genetics 2010; 19(23):4705-4714. 
6. Biasin M, Sironi M, Saulle I, et al. Endoplasmic reticulum aminopeptidase 2 haplotypes 
play a role in modulating susceptibility to HIV infection. AIDS 2013; 27(11):1697-1706. 
7. Cagliani R, Riva S, Fumagalli M, et al. A positively selected APOBEC3H haplotype is 
associated with natural resistance to HIV-1 infection. Evolution 2011; 65(11):3311–3322.  
8. Kane M, Yadav SS, Bitzegeio J, et al. MX2 is an interferon-induced inhibitor of HIV-1 
infection. Nature 2013. 502(7472):563. 
9. Sironi M, Biasin M, Cagliani R, et al. Evolutionary analysis identifies an MX2 haplotype 
associated with natural resistance to HIV-1 infection. Molecular biology and evolution 
2014; 31(9):2402-2414. 
10. Sironi M, Biasin M, Cagliani R, et al. A common polymorphism in TLR3 confers natural 
resistance to HIV-1 infection. The Journal of Immunology 2012; 188(2):818-823. 
13 
 
11. Saulle I, Ibba SV, Torretta E, et al. Endoplasmic Reticulum Associated Aminopeptidase 
2 (ERAP2) Is Released in the Secretome of Activated MDMs and Reduces in vitro HIV-
1 Infection. Front Immunol 10:1648. 
12. Saulle I, Vicentini C, Clerici M, Biasin M. An Overview on ERAP Roles in Infectious 
Diseases. Cells 2020. 9(3):720. 
  
14 
 
FUNDING 
ICONA Foundation is supported by unrestricted grants from Gilead Science, Janssen, 
MSD and ViiV Healthcare. This project was realized with the support of Gilead 
Fellowship Program (Italy) who provided an unrestricted grant. Icona Foundation wrote 
the study project, performed the experiments, analysed the data and finalized the drafting 
of the paper. The funder had no role in data collection, analysis and interpretation, and in 
writing the paper. 
ICONA FOUNDATION STUDY GROUP 
BOARD OF DIRECTORS: A d’Arminio Monforte (President), A Antinori (Vice-
President), M Andreoni, A Castagna, F Castelli, R Cauda, G Di Perri, M Galli, R Iardino, 
G Ippolito, A Lazzarin, GC Marchetti, G Rezza, F von Schloesser, P Viale. SCIENTIFIC 
SECRETARY: A d’Arminio Monforte, A Antinori, A Castagna, F Ceccherini-
Silberstein, A Cozzi-Lepri, E Girardi, S Lo Caputo, C Mussini, M Puoti, CF Perno. 
STEERING COMMITTEE: A Antinori, F Bai, C Balotta, A Bandera, S Bonora, M 
Borderi, A Calcagno, A Capetti, MR Capobianchi, A Castagna, F Ceccherini-Silberstein, 
S Cicalini, A Cingolani, P Cinque, A Cozzi-Lepri, A d’Arminio Monforte, A De Luca, A 
Di Biagio, E Girardi, N Gianotti, A Gori, G Guaraldi, G Lapadula, M Lichtner, S Lo 
Caputo, G Madeddu, F Maggiolo, G Marchetti, L Monno, C Mussini, S Nozza, CF Perno, 
C Pinnetti, M Puoti, E Quiros Roldan, R Rossotti, S Rusconi, MM Santoro, A Saracino, 
L Sarmati.  STATISTICAL AND MONITORING TEAM: A Cozzi-Lepri, I Fanti, L 
Galli, P Lorenzini, A Rodano’, M Macchia, A Tavelli. BIOLOGICAL BANK INMI: F 
Carletti, S Carrara, A Di Caro, S Graziano, F Petroni, G Prota, S Truffa. 
PARTICIPATING PHYSICIANS AND CENTERS: Italy A Giacometti, A Costantini, V 
15 
 
Barocci (Ancona); G Angarano, L Monno, E Milano (Bari); F  Maggiolo, C Suardi 
(Bergamo); P Viale, V Donati, G Verucchi (Bologna); F Castelnuovo, C Minardi, E 
Quiros Roldan (Brescia); B Menzaghi, C Abeli (Busto Arsizio); B Cacopardo, B Celesia 
(Catania);  J Vecchiet, K Falasca (Chieti); A Pan, S Lorenzotti (Cremona); L Sighinolfi, 
D Segala (Ferrara); P Blanc, F Vichi (Firenze); G Cassola, C Viscoli, A Alessandrini, N 
Bobbio, G Mazzarello (Genova); M Lichtner, S Vita, (Latina); P Bonfanti, C Molteni 
(Lecco); A Chiodera, P Milini (Macerata); G Nunnari, G Pellicanò (Messina);  A 
d’Arminio Monforte, M Galli, A Lazzarin, G Rizzardini, M Puoti, A Castagna, ES 
Cannizzo, MC Moioli, R Piolini, D Bernacchia, S Salpietro, C Tincati, (Milano); C 
Mussini, C Puzzolante (Modena); C Migliorino, G Lapadula (Monza); V Sangiovanni, G 
Borgia, V Esposito, F Di Martino, I Gentile, V Rizzo (Napoli); AM Cattelan, S Marinello 
(Padova); A Cascio, M Trizzino (Palermo); F Baldelli, E Schiaroli (Perugia);  G Parruti, 
F Sozio (Pescara); G Magnani, MA Ursitti (Reggio Emilia); M Andreoni, A Antinori, R 
Cauda, A Cristaudo, V Vullo, R Acinapura, D Moschese, M Capozzi, A Mondi, A 
Cingolani, M Rivano Capparuccia, G Iaiani, A Latini, R Gagliardini, MM Plazzi, S 
Savinelli, A Vergori (Roma); M Cecchetto, F Viviani (Rovigo); G Madeddu, A De 
Vito(Sassari); B Rossetti, F Montagnani (Siena);  A Franco, R Fontana Del Vecchio 
(Siracusa); D Francisci, C Di Giuli (Terni); P Caramello, G Di Perri, S Bonora, GC 
Orofino, M Sciandra (Torino); M Bassetti, A Londero (Udine); G Pellizzer, V Manfrin 
(Vicenza); G Starnini, A Ialungo (Viterbo). 
 
CONFICT OF INTEREST DECLARATION 
No competing financial interests exist 
